Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Income from Continuing Operations (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Income from Continuing Operations for 14 consecutive years, with 29789000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 27.16% year-over-year to 29789000.0, compared with a TTM value of 133750000.0 through Dec 2025, down 48.07%, and an annual FY2025 reading of 3656000.0, down 15995.65% over the prior year.
  • Income from Continuing Operations was 29789000.0 for Q4 2025 at Karyopharm Therapeutics, down from 25709000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 38720000.0 in Q4 2021 and bottomed at 57414000.0 in Q1 2021.
  • Average Income from Continuing Operations over 5 years is 32840550.0, with a median of 36843000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations skyrocketed 711.4% in 2021, then plummeted 247.12% in 2025.
  • Year by year, Income from Continuing Operations stood at 38720000.0 in 2021, then tumbled by 199.53% to 38537000.0 in 2022, then fell by 9.14% to 42061000.0 in 2023, then grew by 2.77% to 40894000.0 in 2024, then rose by 27.16% to 29789000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for KPTI at 29789000.0 in Q4 2025, 25709000.0 in Q3 2025, and 35002000.0 in Q2 2025.